PDGFRA exon 14 mutations in GIST are very rare and are imatinib- sensitive. Treatment is...
Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.
| ID | BMA-PDGFRA-EXON14-GIST |
|---|---|
| Tipo | Relevancia terapéutica |
| Situación | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Enfermedades | DIS-GIST |
| Fuentes | SRC-CIVIC SRC-IRIS-OBRIEN-2003 SRC-NCCN-MELANOMA-2025 |
Hechos relativos a la posibilidad de adoptar medidas
| Biomarcador | BIO-PDGFRA |
|---|---|
| Variante | exon 14 mutation (ATP-binding pocket — N659K, N659Y; very rare) |
| Enfermedad | DIS-GIST |
| El nivel de ESCAT | IB |
| Combinaciones recomendadas | imatinib 400 mg/day (1L advanced/metastatic) |
| Resumen de las pruebas | PDGFRA exon 14 mutations in GIST are very rare and are imatinib- sensitive. Treatment is identical to other imatinib-sensitive PDGFRA variants: imatinib 400 mg/day 1L. Per OncoKB and NCCN, all PDGFRA non-D842V mutations are grouped as imatinib-responsive. |
Notas
ESCAT IB. OncoKB Level 1. Source-gap as DIS-GIST.
Utilizado por
No se encuentran referencias inversas en el corpus YAML.